Population pharmacokinetics and pharmacodynamics of hydroxyurea in sickle cell anemia patients, a basis for optimizing the dosing regimen

BACKGROUND: Hydroxyurea (HU) is the first approved pharmacological treatment of sickle cell anemia (SCA). The objectives of this study were to develop population pharmacokinetic(PK)-pharmacodynamic(PD) models for HU in order to characterize the exposure-efficacy relationships and their variability,...

Descripción completa

Detalles Bibliográficos
Autores principales: Paule, Ines, Sassi, Hind, Habibi, Anoosha, Pham, Kim PD, Bachir, Dora, Galactéros, Frédéric, Girard, Pascal, Hulin, Anne, Tod, Michel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2011
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3118100/
https://www.ncbi.nlm.nih.gov/pubmed/21619673
http://dx.doi.org/10.1186/1750-1172-6-30

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3118100/
https://www.ncbi.nlm.nih.gov/pubmed/21619673
http://dx.doi.org/10.1186/1750-1172-6-30

Ejemplares similares